Product Overview
[Drug name]
Generic name: Finasteride tablets
Trade name: PuLiShu Finasteride Tablets 1mg*60 tablets
Pinyin full code: PuLiShu FeiNaXiongAnPian 1mg*6OPian
[Main ingredients]
The main ingredient of this product is finasteride, and its chemical name is N-tert-butyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide. Molecular formula: C23H36N2O2. Molecular weight: 372.55
[Properties]
This product is an orange-red film-coated tablet, which is white or off-white after removing the coating.
[Indications/Main functions]
This product is suitable for the treatment of male baldness (androgenic alopecia), which can promote hair growth and prevent further hair loss. This product is not suitable for women and children.
[Specifications]
1mg*60 tablets
[Usage and dosage]
Oral. The recommended dose is 1mg (1 tablet) each time, once a day, with or without food. Generally, the effects of increased hair growth, increased hair count and/or prevention of further hair loss can only be observed after continuous use of the drug for three months or more. It is recommended to continue using the drug to achieve the maximum therapeutic effect. The therapeutic effect can be reversed within 12 months after stopping the drug.
[Adverse Reactions]
See the instructions for details.
[Contraindications]
This product is not suitable for women and children. People who are allergic to any ingredient of this product and pregnant women or women who may become pregnant are prohibited from using this product.
[Precautions]
1. Direct contact by women - Risk to male fetus This product is not suitable for use by women. Pregnant or potentially pregnant women should not touch broken finasteride tablets to avoid absorption of finasteride and potential harm to the male fetus in the abdomen. Finasteride tablets have an outer film coating to prevent contact with the active ingredients of the drug during normal operation when the tablets are not broken. 2. Effect on PSA (serum prostate-specific antigen) In clinical studies of men aged 18 to 41 years, serum prostate-specific antigen (PSA) dropped from a baseline level of 0.7ng/ml to 0.5ng/ml after taking finasteride 1mg for 12 months. In addition, when finasteride 5mg was used to treat elderly male hair loss patients with benign prostatic hyperplasia (BPH), serum prostate-specific antigen levels dropped by nearly 50%. Other studies have shown that finasteride 5mg can also reduce serum prostate-specific antigen in patients with prostate cancer. These findings can be used to explain the serum prostate-specific antigen levels of men treated with finasteride. Any confirmed increase in serum prostate-specific antigen while taking finasteride 1mg, even if the value is within a reasonable range for men not taking 5α-reductase inhibitors, needs to be evaluated because it indicates the possibility of prostate cancer. Failure to comply with the finasteride 1mg treatment regimen will also affect the results of serum prostate-specific antigen tests. 3.5α-reductase inhibitors increase the risk of well-differentiated prostate cancer In a 7-year prostate cancer prevention trial (PCPT), men over 55 years old who passed routine rectal examination and had PSA ≤ 3.0ng/ml were given finasteride 5mg/day (5 times the dose of 1mg finasteride tablets). When the Gleason score reached 8-10, the incidence of prostate cancer was 1.8% in the finasteride group, which was higher than 1.1% in the placebo group. In a 4-year clinical trial of another 5α-reductase inhibitor (dutasteride,
AVODART) and placebo, the incidence of prostate cancer was similar, 1% in the dutasteride group and 0.5% in the placebo group. The clinical significance of these findings for men using 1mg finasteride is unknown. 5α-reductase inhibitors may increase the risk of well-differentiated prostate cancer. However, whether 5α-reductase inhibitors reduce prostate volume or other factors in the relevant studies affect the results, the above studies have not yet been determined. 4. There is no data showing that finasteride has an effect on the ability to drive and use machines. 5. If any adverse events and/or adverse reactions occur during the use of this product, please consult a doctor. 6. If you use other medicines at the same time, please inform your doctor. 7. Please keep out of reach of children. 8. Use with caution in patients with abnormal liver function. 9. No dosage adjustment is required for patients with renal impairment.
